It is vital for all assays of haemostasis that a full clinical and medication history is received with the requests to aid in interpretation of results.
In particular, full history of anticoagulant usage including type of anticoagulant, dosage (as relevant) and time of last dose is required, if known. Absence of medication history will result in additional testing to screen for anticoagulants which will include a Heparin Anti-Xa and a dilute thrombin time and/or thrombin time. If anticoagulant medication is present then samples will be pre-analytically treated to remove the anticoagulant from the patient plasma to prevent interference with Haemostasis assays. This will include either Hepzyme or DOAC remove of samples. Please note we are unable to remove vitamin K antagonists from samples, thus interpretative comments will be provided on results.
| Test | Non-urgent |
|---|---|
| Platelet Aggregation | Non-urgent 7 days |
| Prolonged APTT investigation | Non-urgent 7 days |
| AT/Hep binding | Non-urgent 7 days |
| Factor X Assay | Non-urgent 7 days |
| Factor XI Assay | Non-urgent 7 days |
| Factor XI Inhibitor Assay | Non-urgent 7 days |
| Factor XII Assay | Non-urgent 7 days |
| Factor XIII alpha subunit | Non-urgent 7 days |
| Factor II Assay | Non-urgent 7 days |
| Factor V Assay | Non-urgent 7 days |
| Factor VII Assay | Non-urgent 7 days |
| Factor VIII Assay | Non-urgent 7 days |
| Factor IX Bethesda Assay Nijmegen Modification | Non-urgent 7 days |
| Intrinsic Bethesda Assy Nijmegen modification | Non-urgent 7 days |
| Factor VIII Inhibitor Assay | Non-urgent 7 days |
| Factor VIII Inhibitor Screen | Non-urgent 7 days |
| Factor IX Assay | Non-urgent 7 days |
| Factor IX Inhibitor Screen | Non-urgent 7 days |
| Fibrinogen Antigen | Non-urgent 7 days |
| Lupus Investigation | Non-urgent 7 days |
| Protein C | Non-urgent 7 days |
| APC Sensitivity Ratio | Non-urgent 7 days |
| PFA 100 | Non-urgent 7 days |
| Protein S (Antigen and Activity) | Non-urgent 7 days |
| PT Normal Plasma Correction | Non-urgent 7 days |
| ROTEM including EXTEM, FIBTEM and NATEM | Non-urgent 7 days |
| Thrombin Time | Non-urgent 7 days |
| VWF RiCof (and VWF Activity) | Non-urgent 7 days |
| VWF Antigen | Non-urgent 7 days |
| vWF Collagen Binding Assay | Non-urgent 30 days |
| INR | Non-urgent 3 days |
| Platelet Nucleotides | Non-urgent 4 weeks |
| Platelet Nucleotide Release Assay | Non-urgent 7 Days |
| Prothrombin G20210A | Non-urgent 2 weeks |
| Factor V Leiden | Non-urgent 2 weeks |
| Dabigatran Assay | Non-urgent 14 days |
| Rivaroxaban Assay | Non-urgent 14 days |
| Apixaban Assay | Non-urgent 14 days |
| Edoxaban Assay | Non-urgent 14 days |
| ADAMTS13 including activity and inhibitor** | Non-urgent 7 days |
| vWF Multimeric Analysis | Non-urgent 30 days |
| Thrombin Induced Lysis Time | Non-urgent 30 days |
| Plasminogen | Non-urgent 30 days |
| Plasmin inhibitors | Non-urgent 30 days |
| t-PA antigen | Non-urgent 30 days |
| PAI-1 antigen | Non-urgent 30 days |
| Argatroban | Non-urgent 14 days |
| Emicizumab Profile | Non-urgent 14 days |
| Heparin Induced Thrombocytopenia Screen | Non-urgent 14 days |